- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT03193593
Study to Evaluate EB-001 in Reducing Musculoskeletal Pain
Phase 2 Placebo-Controlled, Double Blind, Ascending Dose Cohort Study to Evaluate Safety and Efficacy of EB-001 IM Injections in Reducing Musculoskeletal Pain in Subjects Undergoing Elective Augmentation Mammoplasty (Breast Augmentation)
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
This study will evaluate the safety and efficacy of EB-001 in decreasing post-surgical pain in patients undergoing surgical breast augmentation with subpectoral placement of the implants. Intramuscular (IM) injection of EB-001 into the PM bilaterally during surgery may decrease pain related to stretching of the PM by the implants.
The safety objective is to determine the safety and tolerability of single intraoperative treatment of EB-001 IM injections into the PM in subjects undergoing breast augmentation with subpectoral implants.
The efficacy objective is to evaluate the efficacy of intraoperative administration of EB-001 IM into the PM in reducing the pain and use of rescue pain medications in subjects undergoing breast augmentation with subpectoral implants.
Type d'étude
Inscription (Réel)
Phase
- Phase 2
Contacts et emplacements
Lieux d'étude
-
-
California
-
Pasadena, California, États-Unis, 91105
- Lotus Clinical Research
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Women 18 to 55 years of age, inclusive
- Women who are in good health as determined by medical history, physical examination, clinical laboratory studies, ECGs, vital signs, and Investigator judgment
Scheduled to undergo primary breast augmentation under general anesthesia (endotracheal or otherwise) with:
- Sub-pectoral implants placement,
- Infra-mammary surgical approach,
- Implant size between 250 and 400cc and
- Non-textured saline breast implants
- American Society of Anesthesiologist (ASA) Physical Class 1-2
- Women of non-childbearing potential or postmenopausal (at least 12 consecutive months of amenorrhea)
- Women of childbearing potential must not be pregnant, lactating, or planning to become pregnant during the study
Women of childbearing potential agreeing to use either:
- a highly effective method of contraception with failures rates less than 1% per year such as implant, intrauterine device (IUD), or confirmed sterilization and sterilization procedure at least 3 months prior to the day of dosing
- dual methods of contraception with overall failures rate less than 1% per year such as injectable, pill, patch, ring, and diaphragm from the day of dosing for 3 months (subjects using oral contraception must have initiated treatment at least 2 months prior to the day of dosing)
- Willing and able to complete protocol requirements and instructions, which includes completion of all required visits, procedures and in-clinic stays until the end of the study
- Willing and able to sign and date IRB-approved informed consent
- Able to speak, read, and understand the language of the informed consent form (ICF) and study questionnaires
Exclusion Criteria:
- History of surgical procedure involving the breast, including, but not limited to, breast augmentation. History of minor localized breast biopsy is not exclusionary if it occurred at least 1 year prior to the screening visit, and if considered not clinically significant in the opinion of the investigator.
- Pre-existing lung disease that could impact subject safety in the opinion of the investigator
- History of smoking within the past two years
- Slow vital capacity that is below 80% of normal value for respective race, age, height, and gender
- Pulse oximetry below 95%
- Body weight less than 50 kg (110 pounds) or a Body Mass Index (BMI) of ≥ 32
- Documented diagnosis of chronic pain condition, or other painful pre-operative condition that, in the opinion of the investigator, may require analgesic treatment in the post-operative period (e.g. significant joint pain, neuropathic pain)
- Known hypersensitivity to any botulinum toxin serotype or to any component of the formulation
- Reported use of any botulinum toxin within 3 months prior to the date of surgery
- Anticipated use of any botulinum toxin of any serotype during the study
- Use of long acting opioids within 3 days or any opioid medication within 24 hours prior to surgery
- Aminoglycoside intake within 48 hours prior to or during surgery
- Pre-existing disorders of the neuromuscular junction (myasthenia gravis, Eaton- Lambert syndrome, or amyotrophic lateral Sclerosis)
- Any past or current medical condition that in opinion of investigator, puts subject at undue safety risk for surgical complications or for use of the investigational product.
- Any clinically significant psychiatric condition that, in opinion of investigator, may interfere with study assessments or protocol compliance
- History of alcohol or drug abuse in the last 3 years, based on investigator judgement
- Current enrollment in an investigational drug or device study or participation in such a study within 30 days or 5 half-lives of the drug, whichever is longer, of entry into this study
- Subject plans to donate blood or plasma from 30 days prior to screening until last follow-up visit (Day 29)
- Reported pain score of 2 or more at screening on the 11-point scale NPRS-A following strength testing with PM activation
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation séquentielle
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Comparateur placebo: Placebo Injections
Intervention: Drug: Placebo Single Saline Injection into the Pectoralis Muscle |
Placebo- Single injection of saline into Pectoralis Muscle
|
Comparateur actif: EB-001 Dose 1
Intervention: Drug: EB-001 1st Dose in escalation paradigm. Single Injection of active drug into the pectoralis muscle |
Single injection of EB-001 into Pectoralis Muscle
|
Comparateur actif: EB-001 Dose 2 (1.6X)
Intervention: Drug: EB-001 2nd Dose in escalation paradigm, 1.6X Dose 1. Single Injection of active drug into the pectoralis muscle |
Single injection of EB-001 into Pectoralis Muscle
|
Comparateur actif: EB-001 Dose 3 (3.3X)
Intervention: Drug: EB-001 3rd Dose in escalation paradigm, 3.3X Dose 1. Single Injection of active drug into the pectoralis muscle |
Single injection of EB-001 into Pectoralis Muscle
|
Comparateur actif: EB-001 Dose 4 (6.7X)
Intervention: Drug: EB-001 4th Dose in escalation paradigm, 6.7X Dose 1. Single Injection of active drug into the pectoralis muscle |
Single injection of EB-001 into Pectoralis Muscle
|
Comparateur actif: EB-001 Dose 5 (10X)
Intervention: Drug: EB-001 5th Dose in escalation paradigm, 10X Dose 1. Single Injection of active drug into the pectoralis muscle |
Single injection of EB-001 into Pectoralis Muscle
|
Comparateur actif: EB-001 Dose 6 (13.3X)
Intervention: Drug: EB-001 6th Dose in escalation paradigm, 13.3X Dose 1. Single Injection of active drug into the pectoralis muscle |
Single injection of EB-001 into Pectoralis Muscle
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Subject's Assessment of Pain Using the Numeric Pain Rating Scale (AUC16h-96h)
Délai: 16 hours to 96 hours following dosing
|
Subject's assessment of pain using the Numeric Pain Rating Scale (1= No Pain, 10= Maximum Pain) for the first 96 hours following injection, expressed as AUC over the 16h to 96h period following dosing.
|
16 hours to 96 hours following dosing
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- EB001-MA201
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Douleur musculo-squelettique
-
Evergrain, LLCINQUIS Clinical Research Ltd.ComplétéSatiété du pain riche en fibres et riche en protéinesCanada
-
Tel-Aviv Sourasky Medical CenterWeizmann Institute of ScienceComplétéChangements de poids corporel | Modification alimentaire | Microbiote gastro-intestinal | Pain | Tests hématologiquesIsraël
-
Ege UniversityComplétéObésité | Index glycémique | Glucose sanguin | PainTurquie
-
University of BergenUniversity of Leipzig; Chalmers University of Technology; Nofima; Paderborn UniversityComplétéHyperglycémie | Prédiabète | Contrôle glycémique | PainNorvège
Essais cliniques sur Placebo
-
SamA Pharmaceutical Co., LtdInconnueBronchite aiguë | Infection aiguë des voies respiratoires supérieuresCorée, République de
-
National Institute on Drug Abuse (NIDA)ComplétéConsommation de cannabisÉtats-Unis
-
Heptares Therapeutics LimitedComplétéPharmacocinétique | Des problèmes de sécuritéRoyaume-Uni
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingComplétéMaladie de ParkinsonChine
-
West Penn Allegheny Health SystemComplétéAsthme | Rhinite allergiqueÉtats-Unis
-
ItalfarmacoComplétéDystrophie musculaire de BeckerPays-Bas, Italie
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyComplétéSujets masculins atteints de diabète de type II (T2DM)Allemagne
-
Longeveron Inc.RésiliéSyndrome hypoplasique du cœur gaucheÉtats-Unis
-
Chong Kun Dang PharmaceuticalInconnueHypertension | DyslipidémiesCorée, République de